Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2U (CMT2U) is a subtype of autosonal dominant Charcot-Marie-Tooth disease type 2 characterized by late adult-onset (50-60 years of age) of slowly progressive, axonal, peripheral sensorimotor neuropathy resulting in distal upper limb and proximal and distal lower limb muscle weakness and atrophy, in conjunction with distal, panmodal sensory impairment in upper and lower limbs. Tendon reflexes are reduced and nerve conduction velocities range from reduced to absent. Neuropathic pain has also been associated.
Features include always present findings: Peripheral axonal neuropathy, Steppage gait, Difficulty walking (gait disturbance), and Distal amyotrophy and others; and common findings: Hand muscle weakness. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 4 | Hand muscle weakness, Distal muscle weakness, Hand muscle atrophy |
Brain and nerves | 3 | Peripheral axonal neuropathy, Steppage gait, Difficulty walking (gait disturbance) |
Arms and legs | 3 | Hand muscle weakness, Hand muscle atrophy, Foot dorsiflexor weakness |
MARS1 encodes methionyl-tRNA synthetase 1 (900 aa). Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. Highest expression in Cells Cultured fibroblasts (114.2 TPM) and Brain Cerebellum (111.3 TPM).
Charcot-Marie-Tooth disease axonal type 2U is associated with mutations in the MARS1 gene on chromosome 12.
MARS1 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
Genetic testing for MARS1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 7 always present features, 1 common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease axonal type 2U.
2 publications have been identified in PubMed for Charcot-Marie-Tooth disease axonal type 2U. Research spans Basic Science / Preclinical (100%).
Hytönen MK (2025). [PMID: 39804930](https://pubmed.ncbi.nlm.nih.gov/39804930/). *PLoS Genet*. [Basic Science / Preclinical]
Misra K (2024). [PMID: 39000354](https://pubmed.ncbi.nlm.nih.gov/39000354/). *Int J Mol Sci*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 3:08 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease axonal type 2U